Disruption of the phosphatidylinositol 3-kinase/AKT signaling pathway can lead to apoptosis in cancer cells. Previously we identified a lead sulfonamide that selectively bound to the pleckstrin homology (PH) domain of AKT and induced apoptosis when present at low micromolar concentrations. To examine the effects of structural modification, a set of sulfonamides related to the lead compound was designed, synthesized, and tested for binding to the expressed PH domain of AKT using a surface plasmon resonance-based competitive binding assay. Cellular activity was determined by means of an assay for pAKT production and a cell killing assay using BxPC3 cells. The most active compounds in the set are lipophilic and possess an aliphatic chain of the proper length. Results were interpreted with the aid of computational modeling. This paper represents the first structure-activity relationship (SAR) study of a large family of AKT PH domain inhibitors. Information obtained will be used in the design of the next generation of inhibitors of AKT PH domain function.
Introduction
Pleckstrin homology (PH) domains containing 100-120 amino acids are found in over 500 human proteins 1 and are the 11 th most common domain in the human proteome. 2 A subset of 40 PH domains are known to bind phosphorylated phosphatidylinositol (PI) lipids held in cell membranes. PI phosphorylation and the subsequent binding of PH domain-containing proteins are vital components of signal transduction pathways that regulate cell growth and survival. 3, 4 For example, phosphorylation of PI(4,5)P 2 to produce PI(3,4,5)P 3 (see Figure 1) by PI3K signals the recruitment and binding of AKT to the inner leaflet of the plasma membrane via recognition of the PH domain. 5, 6 This translocation allows phosphorylation of AKT at Thr 308 by the plasma membrane-bound PDPK1. 7 Phosphorylation at the Ser 473 residue occurs either by the ILK, by the kinase activity of AKT itself, or by rictor-mTOR. 8 Once fully phosphorylated, AKT translocates through the cytosol to the nucleus where it phosphorylates a variety of downstream targets. AKT promotes cell survival by activating CREB, 9 and promotes proliferation by activating p70S 6 kinase 10 and GSK-3β 11 which contribute to cyclin D accumulation of cell cycle entry. Furthermore, AKT acts as a mediator for VEGF production and angiogenesis by phosphorylation of mTOR. 12 Given its importance in proliferation and survival signaling, AKT is an important target for cancer drug discovery. 13 Several previous attempts to develop AKT inhibitors have led to compounds that bind to the ATP-binding pocket 14 or behave as allosteric inhibitors. 15 Due to the similarity of this pocket among serine/threonine kinases, achieving target specificity has been difficult. Our previous studies involving a D-3-deoxyphosphatidylinositol ether lipid, DPIEL ( Figure  1 ), 16, 17 provided proof-of-principle for using PH domains as drug targets. [17] [18] [19] [20] [21] [22] [23] [24] DPIEL exhibits a high binding affinity and selectivity for the PH domain of AKT. In addition, DPIEL does not bind to other PH domain-containing proteins, including PDPK1, IRS-1, mSOS, and βARK. Although DPIEL exhibits significant antitumor activity, unfortunately it is not a useful drug candidate because of its pharmacokinetic and pharmacodynamic properties. 16 Previously, we used a crystal structure of the PH domain of AKT and in silico screening to cull from libraries compounds expected to bind to the target domain. 25, 26 Compounds selected from these libraries were purchased or prepared, then tested for binding to AKT and for inhibition of AKT function in several cancer cell lines. Compound 1, a sulfonamide (see Table 1 ), was among the leads identified, and so several analogs of 1 were prepared and tested in vitro. The best analog, compound 29 herein, was then tested in vivo where it exhibited good antitumor activity in a mouse xenograft model of pancreatic cancer cells in immunocompromised mice. 26, 27 This work provided for the first time proof-of-principle for further development of sulfonamides as drugs that bind to the PH domain of AKT, inhibit its function, and as a result exhibit antitumor activity. Presented herein are studies with compounds 2-47, derivatives of 1 that were synthesized and tested in an effort to generate structure-activity relationships (SARs) to guide further development of potential drug candidates.
with water, aqueous NaHCO 3 , and water, dried over anhydrous Na 2 SO 4 , and concentrated in vacuo. The resulting yellow oily residue, crude p-butylbenzenesulfonyl chloride (ca 88% yield), was used without further purification in the next reaction; 1 To a stirred solution of 2-amino-1,3,4-thiadiazole (2.0 g, 19.7 mmol) in pyridine (30 mL) under argon at −20 °C was added crude p-butylbenzenesulfonyl chloride (4.89 g, ca 21 mmol) over 10 min. The reaction mixture was allowed to attain rt and stirred for 16 h. Water (300 mL) was added to quench the reaction. The mixture was extracted with CH 2 Cl 2 , the organic extracts washed with 2N HCl (2 × 150 mL), brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was subjected to flash chromatography on silica gel eluted with CH 2 Cl 2 :MeOH 33:1 to give the product 26 (3.46 g, 11.6 mmol, 59% yield) as a solid, mp 120-121 °C; RP HPLC t R 6.06 min (4.6 × 250 mm C 18 column eluted with CH 3 CN, 0.5 mL/min); 1 -N-(1,3,4-thiadiazol-2-yl) 
4-Tetradecyl

4-Dodecyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide (33)-A
suspension of 2-amino-5-methyl-1,3,4-thiadiazole (150 mg, 1.3 mmol) in pyridine (0.5 mL) was stirred and cooled in an ice bath while p-dodecylbenzenesulfonyl chloride (300 mg, 0.87 mmol) was added slowly. The reaction mixture was allowed to attain rt, then heated in an oil bath at 95 °C for 1 h. The reaction mixture was then cooled, added to aqueous 10% HCl (5 mL), and the resulting mixture extracted with EtOAc (3 × 10 mL). The organic extracts were washed with water, brine, dried over anhydrous Na 2 
2-(5-(4-Dodecylphenylsulfonamido)-1,3,4-thiadiazol-2-yl)acetic Acid (36)-
Distilled water (3.0 mL) and 10% aqueous NaOH (0.65 mL) were added to compound 37 (200 mg, 0.40 mmol) and the mixture was heated under reflux for 2 h. The pH of the solution was then adjusted to 4.0 by addition of 1.0 M HCl, the resulting precipitate was isolated by filtration, washed with cold water, and dried to give the product 36 (161 mg, 0.34 mmol, 85%), R f 0. 34 29 (2.0 g, 11.2 mmol) in pyridine (50 mL) was stirred and cooled in an ice bath while p-dodecylbenzenesulfonyl chloride (4.7 g, 13.5 mmol) was added slowly. The mixture was stirred at rt for 48 h, then heated in an oil bath at 90 °C for 15 min. The reaction mixture was then cooled to rt, poured into aqueous 10% HCl, and extracted with EtOAc (3 × 75 mL). The combined extracts were washed with water (2 × 50 mL), brine (2 × 50 mL), dried over anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was subjected to chromatography on silica gel (70-230 mesh) eluted with CH 2 Cl 2 :MeOH 95:5 to give the product 37 (2.9 g, 5.9 mmol, 53%), R f 0.64 (10% MeOH/CH 2 Cl 2 ). Recrystallization from EtOAc/hexanes gave an analytical sample, mp 110-111 °C; 1 Dodecylphenylsulfonamido)-1,3,4-thiadiazole-2-sulfonamide (40) -A suspension of 5-amino-1,3,4-thiadiazolo-2-sulfonamide 32 (4.10 g, 22.8 mmol) in anhydrous acetonitrile (100 mL) was stirred and cooled in an ice bath. Triethylamine (2.5 g, 25 mmol) and a solution of p-dodecylbenzenesulfonyl chloride (8.6 g, 25 mmol) in anhydrous acetonitrile (60 mL) were added, the reaction mixture allowed to attain rt, and then stirred for 48 h. Volatiles were removed in vacuo and the residue was washed with 10% aqueous HCl (100 mL) and water (100 mL) in order to eliminate salts. 
5-(4-
Surface plasmon resonance (SPR) spectroscopy binding assays-
Competitive binding assays were performed with a Biacore 2000, using the Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore, Piscataway, NJ) as previously described. 26 Briefly, PI-3,4,5-phosphates-biotin labeled liposomes (Echelon Biosciences, Salt Lake City, UT) were immobilized on SA chips (BR-1000-32) at a level of 600 response units (RUs). Small molecule analytes at concentrations ranging from one tenth to ten times the predicted K D were co-injected with 80nM PH domain GST-fusion protein (AKT1) at a flow rate of 30uL/min. Dimethylsulfoxide (DMSO) concentrations in all samples and running buffer were 1% (v/v) or less.
Cell assays
Cellular proliferation: A standard 96-well micro-cytoxicity assay was performed by plating cells at 5,000-10,000 cells per well (depending on cell doubling time) for a growth period of 4 days. Drugs were added directly to the media, dissolved in DMSO at various concentrations ranging from 1 to 50 μM. The endpoint was spectrophotometric determination of the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
Detection of pAKT:
Human BxPC3 pancreatic cancer cells were obtained from the American Type Culture Collection (Rockville, MD). Cells were maintained in bulk culture in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 4.5 g/L glucose, 100 U/mL penicillin and 100 μg/mL streptomycin in a 5% CO 2 atmosphere. Cells were passaged using 0.25% trypsin and 0.02% EDTA. Cells were confirmed to be mycoplasma free by testing them with an ELISA kit (Roche-Boehringer Mannheim, Indianapolis, IN). Drugs were freshly prepared in DMSO at a stock concentration of 10 mM and then added at 10μM final concentration directly into the culture media of the cells for 4 h. Following this treatment, cells were lysed as previously published 26 and equal amounts of total cell lysate were loaded on a pSer 473 -AKT/Total AKT Meso Scale Discovery plate. The plate was read using a Sector Imager 2400A instrument (Meso Scale Discovery protein profiling system, Gaithersburg, MD).
Computational modeling
In a previous study 33 GOLD docking and scoring 34 was reported as the best combination for the analysis of interactions between the AKT PH domain and small molecules. Therefore, the GOLD package was employed for molecular docking studies in this work. During docking, the protein was kept as rigid while the flexibility of the ligand was explored. Flipping of the ring corners in the ligands was considered, and carboxylic acids were deprotonated. No early termination was allowed in docking. Other parameters and procedures were applied as previously described. 33 
Results
Chemistry
The structures, yields, and melting points of compounds 1-47 are given in Table 1 . Compounds 1-4 and 8-10 are listed as being commercially available, but only 2 is inexpensive. Compounds 1-5, 7-10 , and 16 are known and were prepared for this study according to literature procedures. Most of the remaining compounds were prepared by condensation of a 2-amino-1,3,4-thiadiazole nucleophile with an arenesulfonyl chloride electrophile in the presence of pyridine. The 2-amino-1,3,4-thiadiazoles and arenesulfonyl chlorides used were either obtained from commercial sources or were prepared by known methods. Yields of these condensations were generally good to excellent. In some cases, substituent modification followed condensation to produce additional analogs (e.g., saponification of esters 13, 22, and 37 gave acids 12, 21, and 36, respectively). Compounds were purified by column chromatography and/or crystallization. Structures were confirmed by spectroscopic methods and purity ascertained to be ≥95% by TLC analysis or by RP HPLC analysis. Details of the syntheses and compound characterization for compounds 26-40 are given in the Experimental Section. Details of the syntheses and compound characterization data for compounds 1-25 and 41-47 are given in the Supplementary Data that accompanies this paper.
Bioassays
Results from bioassays of compounds 1-47 are given in Table 2 and Figure 2 . Compounds were tested for their ability to compete with the binding of PI(3,4,5)P 3 to the PH domain of AKT (reported as K i ) using a previously described surface plasmon resonance (SPR) competitive binding assay. 26, 27 Compounds 1 and 8 that bear hydrogen atoms at positions R 1 , R 2 , and R 3 and an amino or acetamido substituent at position R 4 , respectively, exhibited no ability to block PI(3,4,5)P 3 binding (K i > 50 μM). As a result, K i values for compounds 2-7 and 9-16 were not determined. Compounds 17-24 that bear hydrogen atoms at positions R 2 and R 3 and a decamido substituent at position R 4 , but vary at R 1 , were shown to compete with the binding of PI (3, 4, 5 Following binding experiments, cellular assays were conducted: cellular proliferation (see Table 2 , IC 50 values) and inhibition of AKT activation in BxPC3 cells ( Figure 2) were measured in the presence of compounds 1-47. Cellular activity tracks reasonably well with the K i values. Compounds 1-16 with an amino or acetamido substituent at R 4 were inactive. Several compounds bearing a decanamido substituent at R 4 showed some activity in one or both assays (e. g., 17, 19, 20, and 23) . The best activities were exhibited by compounds 29, 30, 33-35, and 37 that possess C 12 H 25 or C 14 H 29 substituents at R 4 and in some cases an R 1 substituent at position 5 of the thiadiazole ring. Replacement of the R 4 alkyl substituent by phenyl or a PEG amide gave inactive compounds 41-44. Interestingly, compound 45, with a phenyl substituent in place of the thiadiazole ring, did not inhibit phosphorylation of AKT at Ser 473 but did inhibit BxPC-3 cell proliferation. The position of the aliphatic chain also mattered, as compounds 46 and 47 with dodecyl groups ortho and meta to the sulfonamide did not greatly inhibit the production of pAKT but did inhibit BxPC-3 cell proliferation.
Computational Modeling
Molecular docking was used to investigate the binding of compounds 1-47 to the AKT PH domain. The best docking pose of each compound was selected according to the GOLD docking scores, the populations of the pose clusters, and their interactions with the binding pocket. For the purposes of this discussion, compounds 1, 17, 29, and 37 were selected to represent molecules in different chemical subgroups based on the substituent present at position R 4 . The best docking poses of these four molecules and of inositol(1,3,4,5)tetraphosphate (IP 4 ) with the AKT PH domain are illustrated in Figure 3 . In each case, the sulfonamide group interacts with Arg23, Arg25, and Lys14 in a manner similar to the best pose exhibited by compound 1. 28 Compounds 2-7 and 8-16 bear amino and acetamido groups at R 4 , respectively, and variable substitution at R 1 . For the most part, these modifications did not result in large changes in the GOLD docking scores (see Table  2 ). Increasing the length of the carboxamide chain at R 4 by replacement of the acetamido group with a decanamido group, as in compounds 17-25, improved the GOLD docking scores by an average of 7. This is consistent with the greater activity of these compounds as evidenced by the measured K i values (Table 2 ).
Compound 29 is representative of the set of compounds 26-32 that possess alkyl substituents of varying length at R 4 . As depicted in Figure 3 , the nitrogen atoms of the thiadiazole ring of 29 form hydrogen bonds with residue Glu17. The dodecyl chain extends from the main binding pocket to the protein surface, where it appears to interact with the hydrophobic residue Phe55. Shorter chains, as in 26, do not reach Phe55, thus weakening the binding. Based on our docking studies, the presence of a too-long chain, as in 31 and 32, changes the binding pose of the thiadiazole and sulfonamide moieties (not depicted). Compounds 29 and 30 that possess alkyl chains of optimal length (C 12 H 25 and C 14 H 29 , respectively) exhibit stronger binding, as suggested by GOLD docking scores and confirmed by experimental observations (see Table 2 ).
As with 29, compounds 33-40 bear an optimal C 12 H 25 chain at R 4 , and in addition, a substituent R 1 on the thiadiazole ring. The R 1 substituents range from nonpolar alkyl groups that vary in size, to more polar substituents containing carboxylic acid, carboxylate ester, and sulfonamide groups. The more polar groups were expected to mimic the phosphate at C-1 of PI (3, 4, 5 In order to improve our inhibitor design capabilities, the flexibility of the PH domain is under study using molecular dynamics and normal mode analysis. 36 By examining both backbone and side chain flexibility, we have found that docking predictions using the apostructure produced results similar to those using more complex structures. In the present case of the AKT PH domain, 12 ns molecular dynamics following rigid docking demonstrated that accounting for protein flexibility did not improve the docking results significantly. The compound 29-PH domain complex was relatively stable, more or less staying bound in the original docked conformation except for the very end of the alkyl tail (see Supplementary Data for a dynamics movie). This suggests our approach to docking ligands into a rigid AKT PH domain structure virtual screening for targets for which complex crystal structures are unavailable has validity, in particular for this series of compounds related to 29. 37 The availability of the crystal structure of the AKT kinase-PH domain with allosteric inhibitors provides additional understanding of this system. 38 Structural alignment with the IP4-PH domain complex indicates that only the far side of loop 3-4 showed a significant difference and the kinase domain disrupts the phospholipid binding site of the PH domain ( Figure 4 ). Therefore our inhibitors will not bind to this state of the PH domain.
Discussion
In recent years, we identified a family of sulfonamides as being AKT inhibitors based on their direct binding to the PH domain and their cellular and in vivo activities. 16, [25] [26] [27] Although there have been other efforts to develop AKT PH domain inhibitors, few SAR studies based on lead compounds and few studies where antitumor properties have been demonstrated in animals have appeared. 18, 23, [39] [40] [41] [42] The present study represents the first large SAR study on sulfonamide AKT PH domain inhibitors.
Based on docking of 1 to the PH domain of AKT, analogs 2-47 were designed, synthesized, tested for binding using an SPR-based assay, and for cellular activity. Modeling suggested that modification at position R 4 would not disturb the best binding mode of 1 since R 4 points away from the PI(3,4,5)P 3 binding pocket (Figure 3) . Compounds with small groups at R 4 , including 1-7 (R 1 variable, R 2 = R 3 = H, R 4 = NH 2 ), 8-16 (R 1 variable, R 2 = R 3 = H, R 4 = acetamido), and 26-28 (R 1 = R 2 = R 3 = H, R 4 = C 4 -C 8 alkyl chain) do not bind significantly to the AKT PH domain as determined by SPR measurements of competitive binding against PI(3,4,5)P 3 . Some compounds with longer amide-derived substituents at R 4 (decanamides 17-24 and PEG-amide 44) exhibited the ability to inhibit PI(3,4,5)P 3 binding (K i < 50 μM), but at best weak cellular activity. SAR analysis also suggested that compounds with an aliphatic chain of the appropriate length at R 4 (e.g., 29 and 30) exhibited the ability to inhibit PI(3,4,5)P 3 binding (K i ) and good cellular activity as measured by inhibition of AKT phosphorylation and a cell survival assay using BxPC3 cells. However, the need to employ both binding and in vitro assays was underscored by the observation that compounds 31 and 32 bearing C 16 H 33 and C 18 H 37 chains, respectively, at R 4 , exhibited low μM values of K i and the lowest IC 50 values in the cell survival assay, but had little effect on AKT activity, as measured by the pAKT/AKT ratio. In addition, replacement of the thiadiazole ring of 29 with a phenyl ring (compound 45) decreased the K i value, and 45 did not inhibit the production of pAKT, but did inhibit BxPC-3 cell proliferation. These observations suggest that cell-based activities depend not only on binding affinity, but also on other properties, such as cell permeability and compound solubility. In addition, off-target effects may occur and confound interpretation of the results. Off target effects of phosphatidylinositol ether lipid analogs (PIAs) led to the discovery that such compounds can activate a single isoform of p38, p38α, in vitro and in vivo. 43 It was concluded that because p38α activation occurs in cancer cells after chemotherapy and in normal cells during inflammatory processes, activation of p38α by PIAs could contribute to the efficacy and/or toxicity of PIAs.
Modeling also suggested that the sulfonamide moieties of strongly bound compounds, such as 29, mimic the phosphate group at C-3 of PI(3,4,5)P 3 by interacting with Arg23, Arg25, and Lys14 (see Figure 3) . As PI(3,4,5)P 3 also interacts with Tyr18, Ile19, and Arg86 through the C-1 phosphate, substituents were introduced at position R 1 to mimic the C-1 phosphate. Compounds 18-25, 33-40 , and 42-43 were of most interest in this regard, but exhibited K i and IC 50 values similar to those of the reference compounds bearing H at R 1 (17, 29, and 41, respectively) . Thus, substitution at R 1 appears to be of lesser importance than was expected.
Although studies have shown that most of the current scoring functions in docking are of limited accuracy and the docking scores usually are not well correlated with experimentally measured binding affinities, 35 in the present study a correlation between the GOLD docking scores and pKi (see Table 2 ) is apparent ( Figure 5 ). Docking suggested that the two outliers, compounds 31 and 32, adopt alternate binding poses due to the steric problems caused by the too-long alkyl chains. This agreement between the GOLD docking scores and the experimentally determined pK i values supports our previous assertion that the combination of GOLD docking and GOLD scoring is appropriate for modeling this system. 33 
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